Quality control of protease inhibitors.
Protease inhibitors (PIs) are potent competitive inhibitors of the human immunodeficiency virus (HIV) widely used in the treatment of the acquired immune deficiency syndrome (AIDS) and prescribed in combination with other antiretroviral drugs. So far ten PIs were approved by the United States Food and Drug Administration (FDA) for the treatment of HIV infection. In this mini review, quality control methods of each PI are discussed on the basis of analytical techniques published in the literature. Special attention is given to summarize the LC methods described for the analysis of the selected PIs in both drug substances and products with the available literature till date.
Yekkala
Raja
R
Laboratory for Pharmaceutical Analysis, Faculty of Pharmaceutical Sciences, K.U. Leuven, O&N 2, Postbox 923, Herestraat 49, B-3000 Leuven, Belgium.
Adams
Erwin
E
Van Schepdael
Ann
A
Hoogmartens
Jos
J
D019380:Anti-HIV Agents / Q000032:analysis* / Q000592:standards; D000069446:Atazanavir Sulfate; D002219:Carbamates / Q000032:analysis; D002853:Chromatography, Liquid; D000069454:Darunavir; D004340:Drug Contamination / Q000517:prevention & control*; D005663:Furans; D017320:HIV Protease Inhibitors / Q000032:analysis* / Q000592:standards; D019469:Indinavir / Q000032:analysis; D061466:Lopinavir; D019888:Nelfinavir / Q000032:analysis; D009842:Oligopeptides / Q000032:analysis; D010755:Organophosphates / Q000032:analysis; D011725:Pyridines / Q000032:analysis; D011744:Pyrimidinones / Q000032:analysis; D011753:Pyrones / Q000032:analysis; D011786:Quality Control; D019438:Ritonavir / Q000032:analysis; D019258:Saquinavir / Q000032:analysis; D013449:Sulfonamides / Q000032:analysis